甲基泽伊拉斯特拉 (T-96) 通过抑制MAPK/ERK和NF-κB通路来缓解过敏性喘
Jianan Huang1, Hui Cai2, Xiaofen Ye3
1Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
International archives of allergy and immunology
|March 25, 2024
概括
甲基泽伊拉斯特拉 (T-96) 通过抑制关键的炎症途径,有效地减少过敏喘的呼吸道炎症和过敏反应. 这种天然提取物显示出作为喘管理的新型治疗剂的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 甲基泽伊拉斯特拉 (T-96) 是Tripterygium wilfordii Hook F的提取物,在自身免疫性疾病中表现出免疫调节作用.
- 它对呼吸道炎症状况 (如过敏性喘) 的影响在很大程度上仍未被探索.
研究的目的:
- 在小鼠模型中研究T-96对过敏喘的保护作用.
- 阐明T-96在喘中的作用的潜在分子机制.
主要方法:
- 卵胺 (OVA) 诱导的喘小鼠被用不同剂量的T-96.6治疗.
- 评估了气道过敏反应,肺病理,Th2细胞因子水平 (IL-5,IL-13) 和血清IgE.
- 西部斑点分析用于评估MAPK/ERK和NF-κB信号通路的激活.
主要成果:
- 在喘小鼠中,T-96治疗显著降低了呼吸道过敏反应,炎症细胞透和粘液产生.
- 血清IgE,OVA特异性IgE和Th2细胞因子 (IL-5,IL-13) 的水平下降.
- 在喘小鼠中观察到的p38 MAPK,ERK和p65 NF-κB的增加酸化,T-96的使用取消了.
结论:
- T-96显示出显著的抗炎和抗喘特性.
- 该机制涉及抑制MAPK/ERK和NF-κB信号通路.
- T-96具有作为一种针对过敏性喘的新型治疗剂的潜力.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
291
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
291
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
288
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
288
01:20Asthma: Pathogenesis and Management
394
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
394
01:24Antiasthma Drugs: Methylxanthines
226
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
226
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
297
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
297
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
261
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
261